Our analysis, based on collective studies of a total of 7161 cases of prostate cancer, found that genomic alterations of hepsin (p < 0.0001; odds ratio, 3.95 (95% CI, 2.15–7.23)), particularly its amplification (p < 0.036; odds ratio, 4.16 (95% CI, 1.13–15.3)), were significantly associated with prostate cancer metastasis (1079 cases), compared to non-metastatic cases (6082 cases) (Table 1). Here, HPN is linked to prostate cancer.